BACKGROUND: Nerve-function impairment (NFI) commonly occurs during or after chemotherapy in leprosy and is the key pathological process leading to disability and handicap. We describe the development of a simple clinical prediction rule for estimating the risk of NFI occurrence. METHODS: New leprosy cases who presented to a centre in Bangladesh were recruited and followed up for 2 years in a field setting. We used multivariable regression analysis by Cox's proportional hazards model to identify predictive variables for NFI. Discriminative ability was measured by a concordance statistic. Internal validity was assessed with bootstrap resampling techniques. FINDINGS: 2510 patients were followed up for 2 years, 166 developed NFI. A simple model was developed with leprosy group (either paucibacillary leprosy [PB] or multibacillary leprosy [MB]) and the presence of any nerve-function loss at registration as predictive variables. Patients with PB leprosy and no nerve-function loss had a 1.3% (95% CI 0.8-1.8%) risk of developing NFI within 2 years of registration; patients with PB leprosy and nerve-function loss, or patients with MB leprosy and no nerve-function loss had a 16.0% (12-20%) risk; and patients with MB leprosy with nerve-function loss had a 65% (56-73%) risk. INTERPRETATION: Our prediction rule can be used to plan surveillance of new leprosy patients. Patients at low risk of NFI may need no follow-up beyond their course of chemotherapy (6 months); patients with intermediate risk need a minimum of 1 year of surveillance; and patients with high risk should have at least 2 years of surveillance for new NFI. Current recommendations for surveillance of patients with leprosy (for the duration of chemotherapy only) exclude an important group of patients who are at risk of developing NFI after completion of treatment.
BACKGROUND: Nerve-function impairment (NFI) commonly occurs during or after chemotherapy in leprosy and is the key pathological process leading to disability and handicap. We describe the development of a simple clinical prediction rule for estimating the risk of NFI occurrence. METHODS: New leprosy cases who presented to a centre in Bangladesh were recruited and followed up for 2 years in a field setting. We used multivariable regression analysis by Cox's proportional hazards model to identify predictive variables for NFI. Discriminative ability was measured by a concordance statistic. Internal validity was assessed with bootstrap resampling techniques. FINDINGS: 2510 patients were followed up for 2 years, 166 developed NFI. A simple model was developed with leprosy group (either paucibacillary leprosy [PB] or multibacillary leprosy [MB]) and the presence of any nerve-function loss at registration as predictive variables. Patients with PB leprosy and no nerve-function loss had a 1.3% (95% CI 0.8-1.8%) risk of developing NFI within 2 years of registration; patients with PB leprosy and nerve-function loss, or patients with MB leprosy and no nerve-function loss had a 16.0% (12-20%) risk; and patients with MB leprosy with nerve-function loss had a 65% (56-73%) risk. INTERPRETATION: Our prediction rule can be used to plan surveillance of new leprosy patients. Patients at low risk of NFI may need no follow-up beyond their course of chemotherapy (6 months); patients with intermediate risk need a minimum of 1 year of surveillance; and patients with high risk should have at least 2 years of surveillance for new NFI. Current recommendations for surveillance of patients with leprosy (for the duration of chemotherapy only) exclude an important group of patients who are at risk of developing NFI after completion of treatment.
Authors: W Cairns S Smith; Peter G Nicholls; Loretta Das; Pramila Barkataki; Sujai Suneetha; Lavanya Suneetha; Rupendra Jadhav; P S S Sundar Rao; Einar P Wilder-Smith; Diana N J Lockwood; Wim H van Brakel Journal: PLoS Negl Trop Dis Date: 2009-08-11
Authors: Malcolm S Duthie; Marivic F Balagon; Armi Maghanoy; Florenda M Orcullo; Marjorie Cang; Ronaldo Ferreira Dias; Marco Collovati; Steven G Reed Journal: J Clin Microbiol Date: 2013-12-11 Impact factor: 5.948
Authors: W Cairns S Smith; Alison M Anderson; Stephen G Withington; Wim H van Brakel; Richard P Croft; Peter G Nicholls; Jan Hendrik Richardus Journal: BMJ Date: 2004-05-24
Authors: Malcolm S Duthie; Greg C Ireton; Ganga V Kanaujia; Wakako Goto; Hong Liang; Ajay Bhatia; Jean Marie Busceti; Murdo Macdonald; Kapil Dev Neupane; Chaman Ranjit; Bishwa Raj Sapkota; Marivic Balagon; Javan Esfandiari; Darrick Carter; Steven G Reed Journal: Clin Vaccine Immunol Date: 2008-08-20
Authors: Mathieu Bernier; Sahar S Abdelmoneim; Stuart Moir; Robert B McCully; Patricia A Pellikka; Sharon L Mulvagh Journal: Cardiol Res Pract Date: 2009-07-21 Impact factor: 1.866
Authors: Anna Maria Sales; Dayse Pereira Campos; Mariana Andrea Hacker; José Augusto da Costa Nery; Nádia Cristina Düppre; Emanuel Rangel; Euzenir Nunes Sarno; Maria Lucia Fernandes Penna Journal: Trop Med Int Health Date: 2013-09 Impact factor: 2.622